Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Top Cited Papers
- 1 August 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 9 (8), 2344-2353
- https://doi.org/10.1158/1535-7163.mct-10-0324
Abstract
Cyclin-dependent kinases (CDK) are key positive regulators of cell cycle progression and attractive targets in oncology. SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, respectively. SCH 727965 was selected as a clinical candidate using a functional screen in vivo that integrated both efficacy and safety parameters. Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index. In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background. Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects. SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level. This was associated with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematologic parameters. These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent. Mol Cancer Ther; 9(8); 2344–53. ©2010 AACR.Keywords
Other Versions
This publication has 17 references indexed in Scilit:
- Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesACS Medicinal Chemistry Letters, 2010
- Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer CellsCancer Research, 2006
- Drug development in oncology: classical cytotoxics and molecularly targeted agentsBritish Journal of Clinical Pharmacology, 2006
- Cyclin-Dependent Kinase Pathways As Targets for Cancer TreatmentJournal of Clinical Oncology, 2006
- Unmasking the Redundancy Between Cdk1 and Cdk2 at G2 Phase in Human Cancer Cell LinesCell Cycle, 2006
- Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle controlJournal of Cellular Physiology, 2002
- S and G2 Phase Roles for Cdk2 Revealed by Inducible Expression of a Dominant-Negative Mutant in Human CellsMolecular and Cellular Biology, 2001
- Cell cycle regulation and RNA polymerase IIFrontiers in Bioscience-Landmark, 2000
- Cancer Cell CyclesScience, 1996
- Cyclins and cancer II: Cyclin D and CDK inhibitors come of ageCell, 1994